Premarket Decliner
RFL Rafael Holdings Class B30.17-0.88-2.8%
Premarket:9.00-21.17 (-70.2%)
Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613 (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia
Globe NewswireThu, 28-Oct 7:02 AM
